Skip to Content
Merck
All Photos(1)

Key Documents

Y0001161

Carbasalate impurity B

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-[[2-(Acetyloxy)benzoyl]oxy]benzoic acid, 2-Carboxyphenyl o-acetylsalicylate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H12O6
CAS Number:
530-75-6
Molecular Weight:
300.26
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carbasalate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C16H12O6/c1-10(17)21-14-9-5-3-7-12(14)16(20)22-13-8-4-2-6-11(13)15(18)19/h2-9H,1H3,(H,18,19)

InChI key

DDSFKIFGAPZBSR-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbasalate impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

H C Diener et al.
European neurology, 52(1), 50-56 (2004-07-09)
Recently a new effervescent acetylsalicylic acid (ASA) tablet with high buffering capacity has been developed. In this double-blind, 3-arm, multicenter, parallel-group study, 433 patients were treated either with 1,000 mg effervescent ASA or 50 mg encapsulated sumatriptan or placebo. The
V Kretschmer et al.
Platelets, 12(8), 462-470 (2002-01-19)
With the PFA-100 a sensitive and specific screening test for primary haemostasis has recently become available. An important part of the device is a capillary, providing a defined haemodynamic resistance for the perfusion of the aperture. A modified method to
Hydrolysis of acetylsalicylsalicylic acid and salicylsalicylic acid in aqueous solution.
H Sunada et al.
Chemical & pharmaceutical bulletin, 33(5), 2158-2161 (1985-05-01)
Tamás Fischer
Orvosi hetilap, 150(11), 503-512 (2009-03-05)
The beneficial effect achieved by the treatment of endothelial dysfunction in chronic cardiovascular diseases is already an evidence belonging to the basic treatment of the disease. Given the fact that the vascular system is uniform and consubstantial both physiologically, pathophysiologically
R D Kirchhoefer et al.
Journal of pharmaceutical sciences, 69(5), 550-553 (1980-05-01)
A quantitative high-pressure liquid chromatographic method, using a reversed-phase column and an aqueous acetic acid-methanol solution as the mobile phase, was employed for the determination of O-acetyl-O-salicylsalicylic acid and O-salicylsalicylic acid in pharmaceutical aspirin preparations. The aspirin was dissolved, filtered
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service